Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Research & Development (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Research & Development for 16 consecutive years, with $23.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 21.36% year-over-year to $23.7 million, compared with a TTM value of $135.8 million through Dec 2025, up 24.21%, and an annual FY2025 reading of $135.8 million, up 24.21% over the prior year.
  • Research & Development was $23.7 million for Q4 2025 at Amicus Therapeutics, up from $23.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $85.6 million in Q4 2021 and bottomed at $23.4 million in Q3 2025.
  • Average Research & Development over 5 years is $47.3 million, with a median of $41.1 million recorded in 2023.
  • The sharpest move saw Research & Development plummeted 55.12% in 2023, then skyrocketed 146.52% in 2025.
  • Year by year, Research & Development stood at $85.6 million in 2021, then dropped by 25.38% to $63.9 million in 2022, then crashed by 45.16% to $35.0 million in 2023, then dropped by 13.81% to $30.2 million in 2024, then dropped by 21.36% to $23.7 million in 2025.
  • Business Quant data shows Research & Development for FOLD at $23.7 million in Q4 2025, $23.4 million in Q3 2025, and $60.8 million in Q2 2025.